source
- Sanofi pauses phase 2 bronchiectasis trial of SAR445399 for strategic reasonsSanofi has halted a phase 2 study of its monoclonal antibody SAR445399 in adults with non‑cystic fibrosis bronchiectasis. The trial, which began in April, was a randomized, double‑blind, placebo‑co…
- Eli Lilly removes Gaucher disease gene therapy trial from pipeline, citing unmet internal criteriaEli Lilly has announced the removal of a phase 1/2 study testing its GBA1 gene therapy for Gaucher disease type 1. The program was part of the assets acquired when the company bought Prevail Therap…